Valerio Therapeutics AI Stock Analysis
Valerio Therapeutics (0NWK) AI Stock Analysis
Valerio Therapeutics
(LSE:0NWK)
No summary available
Valerio Therapeutics (0NWK) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- EUR 235.00M
- Dividend Yield
- ―
- Average Volume (3M)
- 7,830
- Price to Earnings (P/E)
- -8.8
- Beta (1Y)
- 0.85
- Revenue Growth
- 203.22%
- EPS Growth
- 62.89%
- Country
- UK
- Employees
- 41
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Valerio Therapeutics Business Overview & Revenue Model
Company Description
Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A. (known as Onxeo SA until June 2023) is a clinical-stage biotechnology company dedicated to the global research and development of oncology treatments. Their focus is on ta...
Valerio Therapeutics Peers Comparison
Overall Rating
FR:IPH50Neutral
FR:ALCLS46Neutral
FR:TNG46Neutral
FR:OSE43Neutral
FR:SIGHT40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | EUR 110.36M | -1.94 | 152.56% | ― | -29.48% | 7.91% | |
| 46Neutral | EUR 71.53M | -0.85 | -319.92% | ― | -5.98% | -8.67% | |
| 46Neutral | EUR 194.24M | -4.18 | -29.36% | ― | 189.81% | 38.50% | |
| 43Neutral | EUR 34.33M | -0.86 | -96.73% | ― | -96.25% | -197.89% | |
| 40Underperform | EUR 18.61M | -1.04 | 52.39% | ― | -610.31% | 43.88% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:0NWK | Valerio Therapeutics | 0.41 | 0.21 | 109.84% | |
| FR:IPH | Innate Pharma S.A. | 0.99 | -0.62 | -38.40% | |
| FR:TNG | Transgene SA | 0.70 | -0.58 | -45.47% | |
| FR:OSE | OSE Immunotherapeutics | 1.46 | -3.95 | -73.01% | |
| FR:SIGHT | GenSight Biologics | 0.08 | -0.03 | -30.91% | |
| FR:ALCLS | Cellectis SA | 0.99 | -3.31 | -77.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
